Reply: Pathophysiological, methodological, and statistical considerations in CGRP monoclonal antibody therapy: A comment on Imai et alShungo Imai, Tsubasa Takizawa, Nobuyuki Takahashi et al.|Journal of the Neurological Sciences|2026Cited by 1